Financial Performance - Total revenue for Q1 2025 reached ¥131,776.64 million, an increase of 7.84% compared to ¥122,195.52 million in the same period last year[2] - Operating profit decreased by 21.31% to ¥40,624.71 million from ¥51,626.39 million year-on-year[2] - Net profit attributable to shareholders fell by 22.90% to ¥24,414.57 million, down from ¥31,667.40 million in the previous year[2] - Basic earnings per share decreased to ¥0.12, a decline of 22.90% from ¥0.16 in the same period last year[2] - The weighted average return on equity decreased by 1.00 percentage point to 2.17% from 3.17% year-on-year[2] Assets and Equity - Total assets increased by 2.31% to ¥1,623,534.38 million from ¥1,586,952.22 million at the beginning of the period[2] - Shareholders' equity attributable to the company rose by 2.19% to ¥1,138,285.00 million from ¥1,113,870.44 million[2] Strategic Plans - The company plans to enhance production and sales coordination and control costs to improve profitability[4] Market Conditions - The decline in profit was attributed to a greater decrease in product prices compared to the increase in sales volume[3][4] - The company does not foresee any uncertainties affecting the accuracy of this earnings report[5]
天坛生物(600161) - 2025 Q1 - 季度业绩